Lilly Tries New Neuro Approach With Disarm Buyout
Executive Summary
Deal Snapshot: Lilly bets $135m on biotech’s preclinical SARM1 inhibitor program, seeing potential in peripheral neuropathy and possibly some bigger targets in neurology like MS and ALS.
You may also be interested in...
Retrophin Bolsters Portfolio With Orphan Technologies Buyout
The rare disease-focused firm will pay $90m up front to acquire Orphan Technologies and its Phase I/II enzyme replacement therapy for homocystinuria. Earnouts up to $427m are possible as well.
With Lumasiran Pediatric Data, Alnylam Hopes For Approvals In All PH1 Patients
Alnylam shows that lumasiran offers similar safety and efficacy in primary hyperoxaluria type 1 patients who are six or younger as it does in older patients. US and EU regulatory decisions loom.
InCarda Gets $30m Closer To Inhalable AF Drug/Device Therapy
The first close of a series C financing should enable InRhythm to enter Phase III as an inhalable anti-arrhythmic for paroxysmal atrial fibrillation in a medically supervised setting.
Need a specific report? 1000+ reports available
Buy Reports